Floatz logo

Apixaban

Arteriosclerosis

Yonsei UniversitySmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Arteriosclerosis cohort.

Asset / SponsorPhaseRating
Dapagliflozin
University Medical Centre Ljubljana
Phase 4BBB
Glibenclamide
University of Campinas, Brazil
Phase 4BB
Acetylsalicylic Acid
Yonsei University
Phase 4BB
Dipyridamole
UMC Utrecht
Phase 4BB
Plavix
Yonsei University
Phase 4BB

View all 10 →

Same molecule, other indications

Apixaban is also rated in:

venous thromboembolismDormant
BBB
Indicative ·
79 / 100
View asset →
venous thromboembolismDormant
BBB
Indicative ·
79 / 100
View asset →
atrial fibrillationDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →